ANI PHARMACEUTICALS, INC Deferred Revenue, Revenue Recognized
ANI PHARMACEUTICALS, INC (ANIP) reported Deferred Revenue, Revenue Recognized of $300.00 thousand for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-08-06.
Discontinued › Income Statement › Other Income
us-gaap:DeferredRevenueRevenueRecognized1 · last filed 2020-08-06
- ANI PHARMACEUTICALS, INC deferred revenue, revenue recognized for the quarter ending 2020-03-31 was $100.00K, a 212.50% increase year-over-year.
- ANI PHARMACEUTICALS, INC deferred revenue, revenue recognized for the quarter ending 2019-03-31 was $32.00K.
- ANI PHARMACEUTICALS, INC deferred revenue, revenue recognized for fiscal 2019 was $10.10M.
| Period end | Deferred Revenue, Revenue Recognized 3 month | Deferred Revenue, Revenue Recognized 6 month | Deferred Revenue, Revenue Recognized 9 month | Deferred Revenue, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2020-06-30 | $300.00K 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $100.00K 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $10.10M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $56.00K 10-Q · filed 2019-11-06 | |||
| 2019-06-30 | $37.00K 10-Q · filed 2019-08-07 | |||
| 2019-03-31 | $32.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |